Corcept Therapeutics shares jump 22% after hours after Q2 revenue rises to $256.1 million
AI Market Summary
Corcept Therapeutics posted a major Q2 earnings beat, driven by strong revenue growth and a far-above-consensus EPS print. The newly approved oncology drug Lifyorli delivered meaningful first full-quarter sales, supporting management's raised full-year revenue guidance. The after-hours surge reflects a company-specific repricing on improved fundamentals, with limited broader cross-asset impact.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+2.49%
AI Insight · NCCOGOLD2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Corcept Therapeutics (CORT) reported 2024 second-quarter revenue of $256 million, up 31.7% year over year and above the $219 million consensus estimate. Earnings per share came in at $0.36, compared with expectations of $0.02. Newly approved drug Lifyorli delivered $47.6 million in revenue in its first full quarter, supporting a higher full-year revenue outlook of $1.1 billion to $1.2 billion.
